Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | NQO2 | P16083 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5143090 | 0.85 | PIK3CG (0.48) | GSK3BGSK3ATDP1KDM4EALDH1A1 | |
| SCHEMBL700768 | 0.77 | ALDH1A1 (0.56) | TDP1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL5146624 | 0.72 | MEN1 (0.69) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL5145398 | 0.72 | ENPP2 (0.43) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL5145311 | 0.72 | GSK3A (0.51) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL16346518 | 0.71 | HPGD (0.53) | TDP1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL12990390 | 0.71 | GSK3A (0.77) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL3362480 | 0.71 | GSK3A (0.77) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL3362481 | 0.71 | GSK3A (0.77) | GSK3BGSK3AINSRIGF1RTDP1 | |
| SCHEMBL5181927 | 0.71 | SIRT2 (0.46) | KDM4EALDH1A1HPGDMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6918995-B2 | Process for the production of paper | AKZO NOBEL N.V. (NL) | 2005-07-19 | — | — | US | claimed |
| US-20240240026-A1 | Pulverulent Acetylene Black Material, Process for Its Production, and Compositions, Manufactured Articles and Uses Thereof | ORION ENGINEERED CARBONS IP GMBH & CO. KG (DE) | 2024-07-18 | — | — | US | disclosed |
| EP-4341211-A1 | PULVERULENT ACETYLENE BLACK MATERIAL, PROCESS FOR ITS PRODUCTION, AND COMPOSITIONS, MANUFACTURED ARTICLES AND USES THEREOF | Orion Engineered Carbons IP GmbH & Co. KG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
| US-5012870-A | Hydraulic cement | WESTVACO CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| US-4990191-A | Slurry also contains formaldehde-naphalene sulfonate condensate, or inorganic salts | WESTVACO CORPORATION (US) | 1991-02-05 | — | — | US | disclosed |
| US-4057503-A | ACRYLIC RESIN, LAUNDRY SOUR, SULFONATE OR SULFATE DISPERSANT | PENNWALT CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4029625-A | Non-phasing chloroprene polymer adhesive composition and preparation thereof | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1977-06-14 | — | — | US | disclosed |
| US-3941738-A | Non-phasing chloroprene polymer adhesive composition and preparation thereof | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1976-03-02 | — | — | US | disclosed |
| US-3938986-A | ISOPROPYL N-PHENYLCARBAMATE OR ISOPROPYL N-(3-CHLOROPHENYL)CARBAMATE AND 4-CHLOROPHENYL N-METHYLCARBAMATE | PPG INDUSTRIES, INC. (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | GSK3B 2118/4885GSK3A 2087/4885INSR 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.